Management of Extravasation of Cytotoxic Drugs in Children

More documents

Recommendations

Info

Version Control Table Date Version No Summary of Changes Final amendments approved; EIA 20.12.07 V1.0 Completed; document published Changes Made by (Name and Job Title) Jo Blogs Manager All or part of this document can be released under the Freedom of Information Act 2000 This document is to be retained for 10 years from the date of expiry. Policy Template Page 4 of 22
Table of Contents 1. Purpose and Scope ..................................................................................6 2. Definition...................................................................................................6 3. Ownership and Responsibilities................................................................7 4. Monitoring of the patient ...........................................................................7 5. Patient Education......................................................................................7 6. Signs and Symptoms................................................................................8 7. Treatment of Peripheral Line Extravasation..............................................9 8. Treatment of Extravasation from Central Venous Access Devices: PICC’s, Hickman Lines & Portacaths.............................................................12 9. Mixed Extravasations..............................................................................13 10. Documentation ....................................................................................13 11. Monitoring compliance and effectiveness ...........................................14 12. Updating and Review ..........................................................................14 13. Equality and Diversity..........................................................................14 Appendix 1: Drugs commonly used in Paediatric oncology and their classification ..................................................................................................15 Appendix 2: Non- Cytotoxic Extravasation....................................................16 Appendix 3 : Extravasation Kit Contents.......................................................17 Appendix 4 : Guidelines for Best Practice When Administering Intravenous Infusions ........................................................................................................18 Appendix 5: Patient Information Sheet...........................................................19 Appendix 6 - References ...............................................................................20 Appendix 7.Initial Equality Impact Assessment Screening Form ...................21 Management of Extravasation of Cytotoxic Drugs in Children Ratified: Review: 5
Page 1 and 2: Document Title Management of Extrav
Page 3: Management of Extravasation of Cyto
Page 7 and 8: 3. Ownership and Responsibilities 3
Page 9 and 10: 7. Treatment of Peripheral Line Ext
Page 11 and 12: DMSO (Dimethyl Sulphoxide): DMSO is
Page 13 and 14: 9. Mixed Extravasations In the even
Page 15 and 16: Appendix 1: Drugs commonly used in
Page 17 and 18: Appendix 3 : Extravasation Kit Cont
Page 19 and 20: Appendix 5: Patient Information She
Page 21 and 22: Appendix 7.Initial Equality Impact

Management of Extravasation of Cytotoxic Drugs in Children

Create successful ePaper yourself

Delete template?

Save as template?